Cerenome (CNSY) Q3 2026 Earnings Call Transcript
Cerenome (CNSY) reported Q3 2026 earnings, highlighting progress in diagnostics and therapeutics. CNSide Diagnostics is on track for 1,250 annualized tests and exceeded 150M covered lives. REYOBIQ trials are advancing, with Phase II enrollment completed for ReSPECT-GBM and interim data presented for ReSPECT-LM. The company aims for mid-2027 top-line data and FDA alignment for next steps.
How this was made

The 30-second read
Why it matters
The disclosed trial milestones represent the first public data on enrollment completion and interim safety, which are key value drivers for the company.
Market read
First‑time trial progress news could move CNSY shares; broader biotech sector may benefit.
What to watch
Potential regulatory delays or manufacturing scale‑up challenges could temper upside.
Background
Cerenome's Q3 2026 earnings call focused on clinical trial updates for its lead radiopharmaceutical REYOBIQ.
Ticker impact
Cerenome disclosed closure of Phase II enrollment for its REYOBIQ GBM trial and presented interim Phase II data for the ReSPECT-LM trial at the Society of Neuro-Oncology meeting.
likely upward pressure as investors price in favorable trial milestones.
First disclosure of trial enrollment completion and interim safety results for a radiopharmaceutical targeting CNS cancers, a material catalyst for a biotech.
Market effects
strengthens outlook for CNS‑targeted radiopharmaceuticals and may boost peer biotech sentiment.
U.S. biotech sector could see modest gains.
limited to specialty oncology investors.
Counterpoint
Trial data may be early; investors should watch for later efficacy readouts before committing.
Key entities
- companyCerenome
Biotech developing REYOBIQ for CNS cancers.
- productREYOBIQ
Liposomal targeted radiopharmaceutical in Phase II trials.

